Management of early rectal cancer: Any role for adjuvant ...

Management of early rectal cancer:

Any role for adjuvant chemotherapy?

Andrés CervantesProfessor of Medicine

ESMO PRECEPTORSHIP PROGRAM

TME surgery

Optimal staging by MRI

Pathological assessment of the quality of surgery

Preoperative radiation or chemoradiation

Integration of knowledge in a multidisciplinary team approach

Selective approach for preoperative treatment

CURRENTS CONCEPTS IN RECTAL CANCER

DIAGNOSIS AND THERAPY


IMPROVEMENT IN RECTAL CANCER TREATMENT OUTCOMES IN NORWAY

Local Recurrence Distant Metastases

Distant metastases 4x greater risk than local recurrence

Guren MG, et al Acta Oncol 2015; 54:1714-1722.

ADJUVANT THERAPY FOR LOCALIZED

RECTAL CANCER

Ann Oncol 2017; 28(suppl 4):iv22-iv40.

ESMO PRECEPTORSHIP PROGRAM 7

MRI Staging

MDT discussion

Preoperative treatment if indicated

TME Surgical resection

Pathology assessment and estimation of risk

Postoperative chemotherapy if indicated

CURRENT APPROACH TO RECTAL CANCER

8

THE ROLE OF ADJUVANT CHEMOTHERAPY IN LOCALISED RECTAL CANCER: WHAT IS THE EVIDENCE WE HAVE?

• The pre-TME/preoperative RT or ChRT data• The TME/preoperative RT or ChRT data• How to integrate ChT in patients with locally

advanced disease?


THE ROLE OF ADJUVANT CHEMOTHERAPY IN

LOCALISED RECTAL CANCER: WHAT IS THE

EVIDENCE WE HAVE IN THE PRE-TME PRE-

RT/CHRT PREOPERATIVE ERA?

American Intergroup

Quasar

Japanese Society of Colon and Rectal Meta-analysis on individual data

Cochrane Meta-analysis on individual data


THE ROLE OF SYSTEMIC CHEMOTHERAPY IN

LOCALISED RECTAL CANCER:

Gunderson et al. J Clin Oncol 2004


The American Intergroup* Pooled Analysis

* NSABP, NCCTG and US-GI Intergroup

THE ROLE OF SYSTEMIC CHEMOTHERAPY IN

LOCALISED RECTAL CANCER:

The QUASAR Collaborative Group. Lancet 2007; 370:2020.


The QUASAR TRIAL

UK QUASAR

uncertain

indication trial

Approx 30% rectal.

5yr survival 5 yr recurrence

Chemo No

chemo

P-

value

Chemo No

chemo

P-

value

Whole cohort 80.3% 77.4% 0.02 22.2% 26.2%, 0.001

Rectal subgroup p=0.05 19.6% 26.8%, 0.005

The QUASAR Collaborative Group. Lancet 2007; 370:2020.

WHAT IS THE EVIDENCE WE HAVE?

The Quasar trial

Sakamoto et al. Br J Cancer 2007

WHAT IS THE EVIDENCE WE HAVE?The Japanese Society of Cancer of Colon and Rectum Meta-analysis on UFT trials

2012


The Cochrane Meta-analysis

Petersen et al, Cochrane Data Base of Systenatic Rev 2012; CD004078

Petersen et al, Cochrane Data Base of Systenatic Rev 2012; CD004078

17



advanced disease?

18

THE ROLE OF ADJUVANT CHEMOTHERAPY IN LOCALISED RECTAL CANCER: WHAT IS THE EVIDENCE WE HAVE IN THE TME/PREOPERATIVE RT OR CHRTERA?

• Chronicle trial • Proctor/script trial • Meta-analysis by Breugom on

individual data from 4 trials and 1200 pts

• Adore trial• CAO/ARO/AIO-04 trial

CHRONICLE TRIAL: ASSESSING THE VALUE OF ADJUVANT

CHEMOTHERAPY IN THE TREATMENT OF RECTAL CANCER AFTER

PREOPERATIVE CHEMORADIATION

Glynne Jones et al. Ann Oncol 2014; 25:1356

Glynne Jones et al. Ann Oncol 2014; 25:1356

Target population 800 pts

Primary end point: DFS at 3 years (HR:0.75)

Accrued nr. Patients 113

Underpowered to detect any potential benefit of

Chemotherapy

HR for DFS: 0.80 (95%CI: 0.38-1.69; p:0.56)

HR for OS: 1.18 (95%CI: 0.43-3.26; p:0.75)

WHAT IS THE EVIDENCE WE HAVE? The Chronicle trial

Breugom et al, Ann Oncol 2015; 26:696-701

PROCTOR/SCRIPT TRIAL: ASSESSING THE VALUE OF

ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF

RECTAL CANCER AFTER PREOPERATIVE

CHEMORADIATION OR 5X5 RADIATION


Primary end point: OS at 5 years improved from 60 to 70%

Accrued nr. Patients 437 over 14 years

Underpowered to detect any potential benefit of Chemotherapy

5 year OS for observation: 79.2%

5 year OS for adj therapy: 80.4%

HR for DFS: 0.80 (95%CI: 0.60-1.07; p:0.13)

HR for OS: 0.93 (95%CI: 0.61-1.29; p:0.73)

22

Breugom et al. Lancet Oncol 2015; 16:200-207.

WHAT IS THE EVIDENCE WE HAVE? The Breugom’s Meta-analysis

Adding Oxaliplatin to 5-FU based adjuvant therapy in

localised colon/rectal cancerTrial N Control Exp. Stag

eDFS HRP value

OS HRP value

AbsoluteGain in OS

G3NeuroTox

MOSAIC1 2246 FULV2 FOLFOX4 II/III 0.800.003

0.840.046

4,2% at 6 ystage III

12%

NSABP-C072 2407 FULV Roswell

FLOX II/III 0.800.0034

0.820.002

2,7 at 5 yStage III

8,2%

XELOXA3 1886 FULVMayo

CAPEOX III 0.800.0038

0.830.04

6 % at 7 y 11%

1André T, et al. J Clin Oncol 2007; 27:3109-3116. 2Kuebler JP, et al. J Clin Oncol 2007; 25:2198-2204.3Schmoll HJ et al. J Clin Oncol 2015; 33:3733-3740.

Adding Oxaliplatin to 5-FU based adjuvant therapy in

localised colon/rectal cancerTrial N Control Exp. Stag

eDFS HRP value

OS HRP value

AbsoluteGain in OS

G3NeuroTox

MOSAIC1 2246

FULV2 FOLFOX4 II/III 0.800.003

0.840.046

4,2% at 6 ystage III

12%

NSABP-C072 2407

FULV Roswell

FLOX II/III 0.800.0034

0.820.002

2,7 at 5 yStage III

8,2%

XELOXA3 1886

FULVMayo

CAPEOX III 0.800.0038

0.830.04

6 % at 7 y 11%

AIO044 1233

FU mFOLFOX6

II/III 0.790.030

0.96NS

0.7 at 3 y 9%

NSABP R045 1284

FU/Cape

+ Oxali II/III 0.94 NS

0.94 NS

NR 6%

PETACC66 898 Cape + Oxali II/III 1.04 NS

NR NR 8%1André T, et al. J Clin Oncol 2007; 27:3109-3116. 2Kuebler JP, et al. J Clin Oncol 2007; 25:2198-2204.3Schmoll HJ et al. J Clin Oncol 2015; 33:3733-3740. 4Roedel C et al. Lancet Oncol 2015; 16:979-989. 5Allegra CJ et al. J Natl Cancer Inst 2015; 107: pii: djv248.

Hong YS et al. Lancet Oncol 2014


THE ADORE TRIAL

BOLUS 5FU-LVMayo Clinic Schedule

FOLFOX

Rectal Cancer patients who

completed preoperativeLong course

chemoradiationand Surgery with

free marginsypT3-4N0

oranyTN1-2

1:1 Randomization



THE ADORE TRIAL

No observational arm

Randomised phase II trial 80% Power

Unilateral hypothesis


Primary end point: DFS at 3 years improved by

8% from 70 to 78%

Accrued nr. Patients 322 over 3.5 years

ADORE TRIAL: ADJUVANT CHEMOTHERAPY IN STAGE II/III RECTAL CANCER AFTER PREOPERATIVE CHEMORADIATION

DISEASE FREE AND OVERALL SURVIVAL


28



advanced disease?

RECTAL CANCER: ESMO CLINICAL PRACTICE GUIDELINES ANNALS OF ONCOLOGY 2017

Glynne-Jones R et al. Ann Oncol 2017; 28(Suppl 4):iv22-iv40

RECTAL CANCER: ESMO CLINICAL PRACTICE GUIDELINES

Glynne-Jones R et al. Ann Oncol 2017; 28(Suppl 4):iv22-iv40

George TG , et al. Curr Colorectal Cancer Rep 2015; 11:275-280

DOWNSTAGING AFTER NEOADJUVANT

TREATMENT : NEOADJUVANT RECTAL SCORE

NEOADJUVANT RECTAL SCORE

A SERIES OF 158 LOCALLY ADVANCED RECTAL CANCER

PATIENTS TREATED WITH CT-RT

Log Rang Test p: 0.004 (Mantel Cox)

Roselló S, et al. Clin Colorectal Cancer 2017

NEOADJUVANT RECTAL SCORE IN CAO/ARO/AIO04 TRIAL

Fokas E, et al, Ann Oncol 2018 ahead of print

NEOADJUVANT CT PLUS CT-RT VERSUS CT-RT FOLLOWED BY

SURGERY AND ADJUVANT CT IN MRI DEFINED HIGH RISK RECTAL

CANCER: THE PHASE II RADOMIZED VALENCIAN EXPERIENCE

Fernández-Martos et al. Ann Oncol 2015; 26: 1722-1728

Concurrent CRT withCAPOX

CAPOX x 4

MRI defined Locally advanced

Rectal Cancer patientsN=108

1:1 Randomization

S AdjuvantCAPOX

Concurrent CRT withCAPOX

S

POLISH PHASE III TRIAL CRT VS 5X5 AND FOLFOX

S

5x5 FOLFOX 4 x 3

S

RT+5FU LV wk1,5

Ox weekly

35

Primary end point R0 resectionLocally advanced

Unresectable

Locally recurrent

• MRI defined 66%

• Oxaliplatin became

optional

• Short duration FOLFOX

• Weekly Ox single agent

wk 2,3,4

Bujko et al Ann Oncol. 2016;27:834-842.

Primary end point R0 resection

Bujko K, et al. Ann Oncol 2016; 27:834-842

POLISH TRIAL: OVERALL SURVIVAL FAVORS PREOPERATIVE SCPRT + CHRT VERSUS PREOPERATIVE CHEMORADIATION IN

LOCALLY ADVANCED RECTAL CANCER

HR: 0.73 p: 0.046

THE WAY FORWARD: THE PHASE III RADOMIZED RAPIDO TRIAL

PI: Prof. C. van de Velde

CRT withCAPECITABINEWeek 1-6

5x5 RTWeek 1

MRI defined Locally advanced

Rectal Cancer patientsN=920

1:1 Randomization

SURGERYWeek12

AdjuvantCT OPTIONAL

Neoadjuvant XELOX x6Week 3-16

SURGERYWeek 24-28

DFS at 3 years improved by 10% from 50 to 60%


THE ROLE OF ADJUVANT CHEMOTHERAPY IN

LOCALISED RECTAL CANCER: CONCLUSIONS

Adjuvant Chemotherapy is not standard of care for all localized rectal cancer patients

Adjuvant Chemotherapy should be considered for patients at risk after direct surgery without neoadjuvant therapy

Adjuvant Chemotherapy should be also considered after neoadjuvant Chemoradiation for patients with stage ypIII and high risk stage ypII. LoE: II GoR: C

The decision on postoperative Chemotherapy (FU alone or combined with oxaliplatin) should be risk balanced, taking into account both the predicted toxicity for a particular patient and the risk of relapse, and should be made jointly by the individual and the clinician


Thank you

Management of early rectal cancer: Any role for adjuvant ...

Documents